{"text_format":"1","workbook":"xlsx","n_sheets":6,"sheets":["Cover page ","Introduction","Data sheet","Table 1","Table 2","Table 3"],"not_rendered":{"charts":0,"images":2,"macros":1,"external_links":1,"defined_names":220,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Cover page ","index":0,"n_rows":15,"n_cols":1,"rows_kept":15,"cut":false,"hidden":false,"merged":[]}
[]
[]
[]
[]
[]
[]
[]
[]
["Baseline assessment: Glaucoma: "]
["diagnosis and management"]
["NG81"]
[]
[]
["Published: November 2017"]
["Updated: January 2022"]

{"sheet":"Introduction","index":1,"n_rows":23,"n_cols":2,"rows_kept":23,"cut":false,"hidden":false,"merged":[]}
[null,"Baseline assessment tool for glaucoma: diagnosis and management (NICE guideline NG81)"]
[]
[null,"This baseline assessment tool can be used to evaluate whether practice is in line with the recommendations in Glaucoma: diagnosis and management.  It can also help to plan activity to meet the recommendations."]
[]
[null,"The tool can be used by individual services or organisations. Alternatively, an assessment completed with the involvement of all relevant services or organisations would help to develop a picture of activity in the local area."]
[]
[null,"It should be used in conjunction with Glaucoma: diagnosis and management (NICE guideline NG81)."]
[]
[null,"In the first instance, consider whether the guideline is relevant and record the conclusion in the box below."]
[]
[null,"Is the guideline relevant?"]
[]
[]
[null,"The data sheet contains the recommendations from the guideline. Information can be entered about current activity relevant to the recommendation, actions needed to meet the recommendation, deadlines and the names of the responsible leads.  Useful documents can be added as hyperlinks."]
[]
[null,"The table can be adapted to include any other local information that is thought to be useful."]
[]
[null,"If it would be helpful to group the recommendations, for example those that are key priorities for implementation or by deadline, use the filter function in the data menu. "]
[]
[null,"Tools and resources to help put the guidance into practice are available on the NICE website. "]
[]
[]
[null,"National Institute for Health and Care Excellence\nLevel 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT; www.nice.org.uk\n\nCopyright\n© National Institute for Health and Care Excellence 2022. All rights reserved. \n"]

{"sheet":"Data sheet","index":2,"n_rows":101,"n_cols":11,"rows_kept":101,"cut":false,"hidden":false,"merged":[[0,0,0,10]]}
["Baseline assessment tool for Glaucoma: diagnosis and management (NICE guideline NG81)"]
[]
[null,null,null,null,"Number of relevant recommendations",{"$f":"COUNTIF(D8:D102,\"Yes\")","v":0}]
[null,null,null,null,"Number of recommendations met",{"$f":"COUNTIF(F8:F102,\"Yes\")","v":0}]
[null,null,null,null,"Percentage of recommendations met",{"$f":"IF(ISERROR(F4/F3),\"\",F4/F3)","v":""}]
[]
["NICE recommendation","Guideline reference","Year of recommendation","Is the recommendation relevant?","Current activity/evidence","Recommendation met?","Actions needed to implement recommendation","Is there a risk associated with not implementing this recommendation?","Is there a cost or saving?","Deadline","Lead"]
["1.1  Case-finding"]
["The recommendations on case-finding are for primary eye care professionals before referral for diagnosis of chronic open angle glaucoma (COAG) and related conditions, and are separate from a sight test."]
["Before referral for further investigation and diagnosis of COAG and related conditions, offer all of the following tests:\n•\tcentral visual field assessment using standard automated perimetry (full threshold or supra-threshold)\n•\toptic nerve assessment and fundus examination using stereoscopic slit lamp biomicroscopy (with pupil dilatation if necessary), and optical coherence tomography (OCT) or optic nerve head image if available\n•\tintraocular pressure (IOP) measurement using Goldmann type applanation tonometry\n•\tperipheral anterior chamber configuration and depth assessments using gonioscopy or, if not available or the person prefers, the van Herick test or OCT.","1.1.1.",2017]
["Do not base a decision to refer solely on IOP measurement using non-contact tonometry. ","1.1.2",2017]
["Do not refer people who have previously been discharged from hospital eye services after assessment for COAG and related conditions unless clinical circumstances have changed and a new referral is needed. ","1.1.3",2017]
["Before deciding to refer, consider repeating visual field assessment and IOP measurement on another occasion to confirm a visual field defect or IOP of 24 mmHg or more, unless clinical circumstances indicate urgent or emergency referral is needed. ","1.1.4",2017]
["Refer for further investigation and diagnosis of COAG and related conditions, after considering repeat measures as in recommendation 1.1.4, if:\n• there is optic nerve head damage on stereoscopic slit lamp biomicroscopy or\n• there is a visual field defect consistent with glaucoma or\n• IOP is 24 mmHg or more using Goldmann-type applanation tonometry. \n","1.1.5",2017]
["Provide results of all examinations and tests with the referral. ","1.1.6",2017]
["Advise people with IOP below 24 mmHg to continue regular visits to their primary eye care professional. ","1.1.7",2017]
["The following recommendations are for people planning and providing eye care services before referral."]
["People planning and providing eye care services should use a service model that includes Goldmann-type applanation tonometry before referral for diagnosis of COAG and related conditions. ","1.1.8",2017]
["People planning eye care services should consider commissioning referral filtering services (for example, repeat measures, enhanced case-finding, or referral refinement) for COAG and related conditions. ","1.1.9",2017]
["1.2  Diagnosis"]
["To diagnose COAG and related conditions, offer all of the following tests:\n• visual field assessment using standard automated perimetry (central thresholding test), repeated if necessary to establish severity at diagnosis\n• optic nerve assessment and fundus examination using stereoscopic slit lamp biomicroscopy, with pupil dilatation\n• IOP measurement using Goldmann applanation tonometry (slit lamp mounted)\n• peripheral anterior chamber configuration and depth assessments using gonioscopy\n• central corneal thickness (CCT) measurement. \n","1.2.1",2017]
["Adopt professional or Department of Health and Social Care guidance to reduce the risk of transmitting infective agents via contact tonometry or gonioscopy.\n\nSee the Royal College of Ophthalmologists’ ophthalmic services guidance and the Department of Health and Social Care’s guidance on minimising transmission risk of CJD and vCJD in healthcare settings. ","1.2.2",2009]
["Use the van Herick peripheral anterior chamber depth assessment if clinical circumstances rule out gonioscopy (for example, when people with physical or learning disabilities are unable to participate in the examination). ","1.2.3",2009]
["Obtain an optic nerve head image at diagnosis for baseline documentation (for example, a stereoscopic optic nerve head image or OCT). ","1.2.4","2009, amended 2017"]
["After referral, consider an early assessment appointment when there is clinical concern based on the information provided. ","1.2.5",2017]
["At the time of diagnosis of ocular hypertension (OHT), assess risk of future visual impairment, taking account of risk factors such as:\n• level of IOP\n• CCT\n• family history\n• life expectancy. \n","1.2.6",2017]
["1.3  Standard practice for all assessments"]
["Ensure that all of the following are made available at each clinical episode to all healthcare professionals involved in a person’s care:\n• records of all previous tests and images relevant to COAG and OHT assessment\n• records of past medical history which could affect drug choice\n• current systemic and topical medication\n• glaucoma medication record\n• drug allergies and intolerances. ","1.3.1",2009]
["Use alternative methods of assessment if clinical circumstances rule out standard methods (for example, when people with physical or learning disabilities are unable to participate in the examination). ","1.3.2",2009]
["Ensure that all machines and measurement instruments are calibrated regularly according to the manufacturers’ instructions.","1.3.3",2009]
["1.4  Treatment"]
["Take into account any cognitive and physical impairments when making decisions about management and treatment. ","1.4.1",2017]
["Check that there are no relevant comorbidities or potential drug interactions before offering pharmacological treatment. ","1.4.2",2009]
["Treatment for people with OHT"]
["Do not offer treatment to people with OHT who are not at risk of visual impairment within their lifetime. Advise people to continue regular visits to their primary eye care professional, at clinically appropriate intervals. ","1.4.3","2009, amended 2017"]
["Initial treatment for people with OHT"]
["Offer 360° selective laser trabeculoplasty (SLT) to people with newly diagnosed OHT with IOP of 24 mmHg or more (excluding cases associated with pigment dispersion syndrome) if they are at risk of visual impairment within their lifetime (see the recommendation on taking account of risk factors in the section on diagnosis). To help inform their decision, tell people:\n•\tthat having 360° SLT can delay the need for eye drops and can reduce but does not remove the chance they will be needed at all\n•\thow long it may take for their IOP to improve after the procedure\n•\tabout 360° SLT specific side effects and complications and how long they are likely to last\n•\tthat a second 360° SLT procedure may be needed at a later date. ","1.4.4",2022]
["Consider a second 360° SLT for people with OHT if the effect of an initial successful SLT has subsequently reduced over time. ","1.4.5",2022]
["Offer a generic prostaglandin analogue (PGA) to people with OHT with IOP of 24 mmHg or more if they are at risk of visual impairment within their lifetime (see the recommendation on taking account of risk factors in the section on diagnosis) and:\n•\tthey choose not to have 360° SLT or\n•\t360° SLT is not suitable (for example, because they have pigment dispersion syndrome) or\n•\tthey are waiting for 360° SLT and need an interim treatment or\n•\tthey have had 360° SLT but need additional treatment to reduce their IOP sufficiently to prevent the risk of visual impairment.\n\nDemonstrate correct eye drop installation technique and observe the person using the correct technique when eye drops are first prescribed. ","1.4.6",2022]
["Ongoing treatment for people with OHT"]
["Offer another pharmacological treatment to people with an IOP of 24 mmHg or more who cannot tolerate their current treatment. The first choice should be an alternative generic PGA, and if this is not tolerated, offer a beta blocker. If neither of these options is tolerated, offer a non-generic PGA, carbonic anhydrase inhibitor, sympathomimetic, miotic or a combination of treatments. ","1.4.7","2017, amended 2022"]
["Offer a medicine from another therapeutic class (beta-blocker, carbonic anhydrase inhibitor or sympathomimetic) to people with an IOP of 24 mmHg or more whose current treatment is not reducing IOP sufficiently to prevent the risk of progression to sight loss. Topical medicines from different therapeutic classes may be needed at the same time to control IOP.","1.4.8","2009, amended 2017"]
["Refer people to a consultant ophthalmologist to discuss other options if their IOP cannot be reduced sufficiently with 360° SLT or pharmacological treatment or both to prevent the risk of progression to sight loss. ","1.4.9","2009, amended 2022"]
["Offer preservative-free eye drops to people who have an allergy to preservatives or people with clinically significant and symptomatic ocular surface disease, but only if they are at high risk of conversion to COAG. ","1.4.10","2009, amended 2017"]
["Treatment for people with suspected COAG"]
["Do not offer treatment to people with suspected COAG and IOP less than 24 mmHg unless they are at risk of visual impairment within their lifetime. Advise people to continue regular visits to their primary eye care professional, at clinically appropriate intervals. ","1.4.11","2017, amended 2022"]
["Stopping treatment for people with OHT or suspected COAG"]
["Discuss the benefits and risks of stopping treatment with people with OHT or suspected COAG who have both:\n•\ta low risk of developing visual impairment within their lifetime and\n•\tan acceptable IOP. \n\nIf a person decides to stop treatment after this discussion, offer to assess their IOP in 1 month to 4 months with further reassessment if clinically indicated.","1.4.12",2009]
["Treatment for people with COAG"]
["In November 2021 the use of mitomycin-C (MMC) in recommendations 1.4.13 and 1.4.20 to 1.4.22 was off label. See NICE’s information on prescribing medicines. "]
["Treatment for people with advanced COAG"]
["Offer people with advanced COAG, glaucoma surgery with pharmacological augmentation (MMC) as indicated. Give them information on the risks and benefits of surgery. ","1.4.13","2009, amended 2022"]
["Offer people who present with advanced COAG and who are listed for glaucoma surgery, interim treatment with a generic PGA.","1.4.14","2009, amended 2022"]
["Initial treatment for people with COAG"]
["Offer 360° SLT to people with newly diagnosed COAG (excluding cases associated with pigment dispersion syndrome). For people with advanced COAG see the section on treatment for people with advanced COAG and recommendation 1.4.24. To help inform their decision, tell people:\n•\tthat having 360° SLT can delay the need for eye drops and can reduce but does not remove the chance they will be needed at all\n•\thow long it may take for their IOP to improve after the procedure\n•\tabout 360° SLT specific side effects and complications and how long they are likely to last\n•\tthat a second 360° SLT procedure may be needed at a later date. ","1.4.15",2022]
["Consider a second 360° SLT for people with COAG if the effect of an initial successful SLT has subsequently reduced over time. ","1.4.16",2022]
["Offer a generic PGA to people with COAG if:\n•\tthey choose not to have 360° SLT or\n•\t360° SLT is not suitable (for example because they have pigment dispersion syndrome) or\n•\tthey are waiting for an 360° SLT and need an interim treatment or\n•\tthey have previously had 360° SLT but need additional treatment to reduce their IOP sufficiently to prevent the risk of visual impairment.\n\nDemonstrate correct eye drop installation technique and observe the patient using the technique when eye drops are first prescribed. ","1.4.17",2022]
["Ongoing treatment for people with COAG"]
["Encourage people to continue with the same pharmacological treatment unless:\n•\ttheir IOP cannot be reduced sufficiently to prevent the risk of progression to sight loss\n•\tthere is progression of optic nerve head damage\n•\tthere is progression of visual field defect\n•\tthey cannot tolerate the medicine.","1.4.18",2009]
["Ask about adherence to treatment and check the eye drop instillation technique in people with COAG whose IOP has not been reduced sufficiently to prevent the risk of progression to sight loss, despite pharmacological treatment with a generic PGA. ","1.4.19","2009, amended 2022"]
["Offer 1 of the following to people with satisfactory adherence to treatment and eye drop instillation technique whose IOP has not been reduced sufficiently to prevent the risk of progression to sight loss:\n•\ta medicine from another therapeutic class (a beta-blocker, carbonic anhydrase inhibitor or sympathomimetic); topical medicines from different therapeutic classes may be needed at the same time to control IOP or\n•\t360° SLT or\n•\tglaucoma surgery with pharmacological augmentation (MMC) as indicated. ","1.4.20","2009, amended 2022"]
["Consider 360° SLT or glaucoma surgery with pharmacological augmentation (MMC) as indicated for people with COAG who are at risk of progressing to sight loss despite treatment with medicines from 2 therapeutic classes. Give them information on the risks and benefits of surgery. ","1.4.21","2009, amended 2022"]
["Consider 1 of the following for people with COAG who cannot tolerate a pharmacological treatment:\n•\ta medicine from another therapeutic class (a beta-blocker, carbonic anhydrase inhibitor or sympathomimetic) or\n•\tpreservative-free eye drops if there is evidence that the person is allergic to the preservative or has clinically significant and symptomatic ocular surface disease.\n\nAfter treatment with medicines from 2 therapeutic classes, consider 360° SLT or glaucoma surgery with pharmacological augmentation (MMC) as indicated. ","1.4.22","2009, amended 2022"]
["Offer 1 of the following to people with COAG whose IOP has not been reduced sufficiently to prevent the risk of progression to sight loss after glaucoma surgery:\n•\tpharmacological treatment; topical medicines from different therapeutic classes may be needed at the same time to control IOP or\n•\tfurther glaucoma surgery or\n•\t360° SLT or\n•\tcyclodiode laser treatment. ","1.4.23","2009, amended 2022"]
["Offer 1 of the following to people with COAG (including advanced COAG) who prefer not to have glaucoma surgery or for whom glaucoma surgery is not suitable:\n•\tpharmacological treatment; topical medicines from different therapeutic classes may be needed at the same time to control IOP or\n•\t360° SLT (for example in people with systemic comorbidities) or\n•\tcyclodiode laser treatment. ","1.4.24","2009, amended 2022"]
["1.5  Reassessment"]
["Reassessment tests"]
["At each assessment, offer the following tests to people with COAG, people with suspected COAG and people with OHT:\n•\tGoldmann applanation tonometry (slit lamp mounted)\n•\tanterior segment slit lamp examination with van Herick peripheral anterior chamber depth assessment when clinically indicated. ","1.5.1",2017]
["When clinically indicated, repeat gonioscopy, for example, if a previous examination has been inconclusive or there is suspicion of a change in clinical status of the anterior chamber angle. ","1.5.2",2017]
["When clinically indicated, repeat visual field testing using standard automated perimetry (central thresholding test) for people with COAG and those with suspected visual field defects who are being investigated for possible COAG (see table 2 and table 3 for recommended reassessment intervals).","1.5.3","2009, amended 2017"]
["When clinically indicated, repeat visual field testing using either a central thresholding test or a supra-threshold test for people with OHT and those with suspected COAG whose visual fields have previously been documented by standard threshold automated perimetry (central thresholding test) as being normal (see table 1 and table 2 for recommended reassessment intervals). ","1.5.4","2009, amended 2017"]
["When a visual field defect has previously been detected, use the same measurement strategy for each visual field assessment. ","1.5.5",2009]
["When clinically indicated, repeat assessment of the optic nerve head (for example, stereoscopic slit lamp biomicroscopy or imaging).","1.5.6",2017]
["When a change in optic nerve head status is detected by stereoscopic slit lamp biomicroscopy, obtain a new optic nerve head image for the person’s records to provide a fresh benchmark for future assessments. ","1.5.7",2009]
["When an adequate view of the optic nerve head and surrounding area is unavailable at reassessment, people should have their pupils dilated before stereoscopic slit lamp biomicroscopy or optic nerve head imaging is repeated. ","1.5.8",2009]
["When to reassess"]
["People with COAG, suspected COAG and OHT"]
["At each assessment, re-evaluate the risk of conversion to COAG and the risk of sight loss to set time to next assessment. ","1.5.9",2017]
["At each assessment, ask about general health and, if appropriate, factors affecting adherence to treatment, including cognitive impairment and any treatment side effects. ","1.5.10","2009, amended 2017"]
["People with treated OHT (baseline IOP 24 mmHg or more) and a normal optic nerve head and visual field at most recent assessment"]
["For people with treated OHT (baseline IOP of 24 mmHg or more) and a normal optic head and visual field at the most recent assessment:\n•\tuse clinical judgement to assess control of IOP and the risk of conversion to COAG, and\n•\treassess according to table 1. ","1.5.11",2017]
["People with suspected COAG"]
["For people with suspected COAG:\n•\tuse clinical judgement to assess control of IOP and risk of conversion to COAG (optic nerve head damage and visual field defect), and\n•\treassess according to table 2. ","1.5.12",2017]
["People with COAG"]
["For people with COAG:\n•\tuse clinical judgement to assess risk of COAG progression to sight loss, and\n•\treassess according to table 3. ","1.5.13",2017]
["Discharge back to primary care"]
["Discharge people back to primary eye care services if:\n•\tthey were referred for OHT but do not need treatment\n•\tthey were referred for suspected COAG but this is no longer suspected. \n\nAdvise people that they should continue with regular visits to their primary eye care professional, at clinically appropriate intervals. ","1.5.14",2017]
["Give a discharge summary to people who have been assessed and discharged to primary care. Send a copy to their GP and, with patient consent, copy the relevant information to the primary eye care professional nominated by the patient. Advise people to take their discharge summary with them when attending future sight tests. ","1.5.15",2017]
["1.6  Organisation of care"]
["Refer people to a consultant ophthalmologist for consideration of a definitive diagnosis and formulation of a management plan if:\n•\tthey have suspected optic nerve damage or repeatable visual field defect, or both, and\n•\tSLT treatment is suitable (see recommendation 1.4.4 and recommendation 1.4.15 for people with newly diagnosed OHT and COAG).","1.6.1","2009, amended 2022"]
["Diagnosis of OHT and suspected COAG and formulation of a management plan should be made by a suitably trained healthcare professional with:\n•\ta specialist qualification and\n•\trelevant experience.","1.6.2","2009, amended 2017"]
["Be aware that holding an independent or non-medical prescribing qualification alone (without a specialist qualification relevant to the case complexity of glaucoma being managed) is insufficient for managing glaucoma and related conditions. ","1.6.3",2017]
["Healthcare professionals involved in the diagnosis of OHT and COAG suspect status, and preliminary identification of COAG, should be trained in case detection and referral refinement and be able to identify abnormalities based on relevant clinical tests and assessments. They should understand the principles of diagnosis of OHT and COAG and be able to perform and interpret all of the following:\n•\tmedical and ocular history\n•\tdifferential diagnosis\n•\tGoldmann applanation tonometry (slit lamp mounted)\n•\tstandard automated perimetry (central thresholding test)\n•\tcentral supra-threshold perimetry\n•\tstereoscopic slit lamp biomicroscopic examination of anterior segment\n•\texamination of the posterior segment using slit lamp binocular indirect ophthalmoscopy\n•\tgonioscopy\n•\tvan Herick peripheral anterior chamber depth assessment\n•\tCCT measurement. ","1.6.4",2009]
["People with OHT, suspected COAG or COAG should have monitoring and treatment from a trained healthcare professional who has all of the following:\n•\ta specialist qualification\n•\trelevant experience\n•\tability to detect a change in clinical status. ","1.6.5","2009, amended 2017"]
["Healthcare professionals involved in monitoring and treating OHT, suspected COAG and established COAG should be trained to make management decisions on:\n•\trisk factors for conversion to COAG\n•\tcoexisting pathology\n•\trisk of sight loss\n•\tmonitoring and detecting a change in clinical status (for example, visual field changes and stereoscopic slit lamp biomicroscopic examination of anterior segment and posterior segment)\n•\tpharmacology of IOP lowering medicines\n•\teligibility for 360° SLT\n•\ttreatment changes for COAG, suspected COAG and OHT (with consideration given to relevant contraindications and interactions). ","1.6.6","2009, amended 2022"]
["Healthcare professionals should discuss with the responsible consultant ophthalmologist the decision to offer 360° SLT and how it will be performed. Healthcare professionals undertaking 360° SLT should be given support by the responsible consultant ophthalmologist. Training should include:\n•\tthe suitability of the procedure\n•\tlaser safety and procedures\n•\tbenefits and risks of 360° SLT, and how to discuss these with patients and their family members or carers (as appropriate)\n•\tpatient consent. ","1.6.7",2022]
["People with a confirmed diagnosis of OHT or suspected COAG and who have an established management plan may have monitoring (but not treatment) from a suitably trained healthcare professional with knowledge of OHT and COAG, relevant experience and the ability to detect a change in clinical status. The healthcare professional should be able to perform and interpret all of the following:\n•\tGoldmann applanation tonometry (slit lamp mounted)\n•\tstandard automated perimetry (central thresholding test)\n•\tcentral supra-threshold perimetry (this visual field strategy may be used for monitoring OHT or suspected COAG when the visual field is normal)\n•\tstereoscopic slit lamp biomicroscopic examination of the anterior segment\n•\tvan Herick peripheral anterior chamber depth assessment\n•\texamination of the posterior segment using slit lamp binocular indirect ophthalmoscopy. ","1.6.8",2009]
["Healthcare professionals who diagnose, treat or monitor independently of consultant ophthalmologist supervision should take full responsibility for the care they provide. ","1.6.9",2009]
["1.7  Providing information"]
["Ensure that people are offered the opportunity to discuss their diagnosis, referral, prognosis, treatment and discharge so they can take an active part in decision making (see NICE’s guideline on shared decision making). Provide them with relevant information in an accessible format at initial and subsequent visits. This should include telling them:\n•\tabout their specific condition (OHT, suspected COAG and COAG), its life-long implications and their prognosis for retention of sight\n•\tthat COAG in the early stages and OHT and suspected COAG are symptomless\n•\tthat most people having treatment for COAG will have good quality of life and not go blind\n•\tthat once lost, sight cannot be recovered\n•\tthe different types of treatment options, including mode of action, frequency and severity of side effects, and risks and benefits of treatment\n•\tthat glaucoma can run in families and that family members may wish to be tested for the condition\n•\tthe importance of their role in their own treatment – for example, the ongoing regular application of eye drops to preserve sight. ","1.7.1","2009, amended 2017"]
["Ensure that people are given practical information and advice on:\n•\thow to apply eye drops, including technique (punctal occlusion and devices) and hygiene (storage)\n•\tthe need for regular monitoring as specified by the healthcare professional\n•\tmethods of investigation during assessment\n•\thow long each appointment is likely to take and whether the person will need any help to attend (for example, driving soon after pupil dilatation would be inadvisable)\n•\thow to contact the eye clinic liaison officer (ECLO) and what information and assistance they can provide\n•\tsupport organisations and support groups\n•\tcompliance aids (such as dispensers) available from their GP or community pharmacist\n•\tLetter of Vision Impairment (LVI), Referral of Vision Impairment (RVI) and Certificate of Vision Impairment (CVI), registration\n•\tDriver and Vehicle Licensing Agency (DVLA) regulations. ","1.7.2","2009, amended 2017"]

{"sheet":"Table 1","index":3,"n_rows":10,"n_cols":3,"rows_kept":10,"cut":false,"hidden":false,"merged":[]}
["Table 1 Time to next assessment for people being treated for OHT"]
["Conversion from ocular hypertension to chronic open angle glaucoma","Control of intraocular pressure","Time to next assessment"]
["Not detected or uncertain conversion","No","Review management plan and reassess between 1 month and 4 months"]
["Uncertain conversion","Yes","Reassess between 6 months and 12 months"]
["No conversion detected","Yes","Reassess between 18 months and 24 months"]
["Conversion","No or yes","See recommendations on diagnosis and reassessment of chronic open angle glaucoma"]
["Use clinical judgement to decide when the next appointment should take place within the recommended"]
["interval, including the need to assess the impact of any new treatments started."]
["Uncertain conversion includes having insufficient accurate information (perhaps because the person was "]
["unable to participate in the assessment)."]

{"sheet":"Table 2","index":4,"n_rows":10,"n_cols":3,"rows_kept":10,"cut":false,"hidden":false,"merged":[]}
["Table 2 Time to next assessment for people with suspected COAG"]
["Conversion to chronic open angle glaucoma","Control of intraocular pressure","Time to next assessment"]
["Not detected or uncertain conversion","No","Review management plan and reassess between 1 month and 4 months"]
["Uncertain conversion","Yes","Reassess between 6 months and 12 months"]
["No conversion detected","Yes","Reassess between 12 months and 18 months"]
["Conversion","No or yes","See recommendations on diagnosis and reassessment of chronic open angle glaucoma"]
["Use clinical judgement to decide when the next appointment should take place within the recommended"]
["interval, including the need to assess the impact of any new treatments started."]
["Uncertain conversion includes having insufficient accurate information (perhaps because the person "]
["was unable to participate in the assessment)."]

{"sheet":"Table 3","index":5,"n_rows":11,"n_cols":3,"rows_kept":11,"cut":false,"hidden":false,"merged":[]}
["Table 3 Time to next assessment for people with COAG"]
["Progression of chronic open angle glaucoma","Control of intraocular pressure","Time to next assessment"]
["Not detected","No","Review treatment plan and reassess between 1 month and 4 months"]
["Uncertain progression or progression","No","Review treatment plan and reassess between 1 month and 2 months"]
["No progression detected and low clinical risk","Yes","Reassess between 12 months and 18 months"]
["No progression detected and high clinical risk","Yes","Reassess between 6 months and 12 months"]
["Uncertain progression or progression","Yes","Review treatment plan and reassess between 2 months and 6 months"]
["Use clinical judgement to decide when the next appointment should take place within the recommended"]
["interval, including the need to assess the impact of any new treatments started."]
["Uncertain conversion includes having insufficient accurate information (perhaps because the person was unable "]
["to participate in the assessment)."]